Primary amyloidosis (PA) is a systemic disease associated with abnormal deposition of proteins called amyloid in various organs and tissues. This leads to dysfunction and can have a serious impact on the general condition of the patient. Amyloidosis can be caused by a number of different diseases, but primary amyloidosis, most often associated with multiple myeloma, occurs as a result of excessive production of the immunoglobulin light chain. Clinical and laboratory manifestations of PA can vary depending on the location of amyloid deposition and the organs affected, but always require careful examination and treatment.
History of the disease and interesting historical facts
Primary amyloidosis was first described in the medical literature in the early 19th century. The word amyloid itself comes from the Latin amylum, meaning starch, due to the similarity of the morphological properties of amyloid deposits to starch. In 1854, German pathologist Albert Meyer independently described the abnormal deposits that were observed in tissues in various diseases, noting their characteristic features. Over the following decades, scientists continued to study diseases caused by amyloidosis, including primary amyloidosis. Interestingly, in the 20th century, it was established that amyloid can occur not only in myeloma, but also in various inflammatory and neoplastic conditions, which expanded the understanding of the pathogenesis of this disease and opened up new avenues for its diagnosis and treatment.
Epidemiology
Epidemiological studies show that primary amyloidosis is relatively rare, with an incidence of about 8-12 cases per 1 million people per year. This disease is predominantly diagnosed in older people, with a peak incidence between 60 and 70 years. Statistics indicate that primary amyloidosis occurs in men 2-3 times more often than in women. It has also been established that in certain ethnic groups, such as African Americans, the risk of developing PA may be higher, which also requires further study in terms of genetic and environmental factors.
Genetic predisposition to this disease
Current research confirms the presence of a genetic predisposition to primary amyloidosis. In particular, several genes have been identified that may be involved in the pathogenesis of this condition. Among them, mutations in genes responsible for the synthesis of immunoglobulins stand out. Studies have found that the expression of certain genes, such as the immunoglobulin light chain gene (IGL) and the heavy chain gene (IGH), may be associated with an increased risk of amyloidosis. About 15% patients with primary amyloidosis may have a familial predisposition, which emphasizes the need for genetic counseling for those at risk.
Risk factors for the development of this disease
Risk factors for primary amyloidosis can be divided into several categories:
- Chronic inflammatory conditions such as chronic infection or systemic lupus erythematosus.
- Some types of cancer, especially hematological malignancies, including multiple myeloma.
- Age over 60 years, which is a significant risk factor for developing amyloidosis-related diseases.
- Family history of amyloidosis, indicating a possible hereditary predisposition.
- Genetic mutations associated with immunoglobulins.
These factors highlight the importance of continuous monitoring of patients at risk.
Diagnosis of this disease
Diagnosis of primary amyloidosis involves a multi-step approach:
- Main symptoms: Symptoms may vary, but the most common are weakness, swelling, dyspnea, and kidney and heart problems.
- Laboratory tests: Blood and urine tests may show the presence of Bence Jones protein and may also reveal signs of kidney failure or anemia.
- Radiological examinations: Ultrasound, CT and MRI can be used to assess the condition of internal organs.
- Other types of diagnostics: A tissue biopsy (eg, adipose tissue or mucosa) can confirm the presence of amyloid deposits.
- Differential diagnosis: It is important to distinguish primary amyloidosis from other diseases with similar symptoms, such as diabetes or heart disease.
A comprehensive approach to diagnostics allows us to accurately determine the presence of amyloidosis and its impact on the patient’s body.
Treatment
Treatment of primary amyloidosis is complex and includes several areas:
- General treatment: Includes symptom management and supportive care to improve quality of life.
- Pharmacological treatment: Drugs are used to reduce the production of amyloidogenic proteins, including melphalan and dexamethasone.
- Surgical treatment: In some cases, transplantation of organs affected by amyloid deposits may be required.
- Other types of treatment: New approaches such as self-antigen-directed therapy are being explored, and there is high interest in the use of monoclonal antibodies.
All treatment methods are discussed with the patient and selected individually in accordance with the condition.
List of medications used to treat this disease
The main drugs used to treat primary amyloidosis include:
- Melphalan
- Dexamethasone
- Bortezomib
- Tasilolimus
- Daratumumab
The list of drugs may be expanded depending on clinical recommendations and individual indications.
Disease monitoring
Monitoring of primary amyloidosis includes:
- Control stages: Regular check-ups with a doctor, blood and urine tests to assess organ function.
- Forecast: The prognosis depends on the stage of the disease and the time of initiation of treatment, but timely diagnosis significantly improves the outcome.
- Complications: Possible complications include heart failure, renal failure and other organ dysfunctions, which require intensive monitoring.
Careful monitoring of the patient's condition helps prevent the development of serious complications.
Age-related features of the disease
Primary amyloidosis is most often seen in older people. In younger patients, the disease may be more aggressive and have different clinical manifestations. In older people, amyloidosis is often accompanied by comorbidities, which can complicate diagnosis and treatment. In children, primary amyloidosis is extremely rare, but if such symptoms appear, immediate diagnosis and treatment are necessary.
Questions and Answers
- What is primary amyloidosis? It is a disease associated with abnormal deposition of amyloid proteins in organs, leading to their dysfunction.
- What are the symptoms of primary amyloidosis? Symptoms may include weakness, swelling, shortness of breath, kidney and heart problems.
- How is this disease treated? Treatment includes pharmacological therapy, symptom management, and in some cases surgical techniques.
- Who should be especially wary of primary amyloidosis? Those at risk include the elderly, as well as patients with chronic diseases and a family history of amyloidosis.
- What is the life expectancy of patients with primary amyloidosis? Prognosis depends on the organs involved and the timing of treatment; early treatment can improve outcome significantly.
This article provides extensive information on primary amyloidosis, its characteristics and relevance to clinical practice.
